Latest news with #genomics
Yahoo
a day ago
- Business
- Yahoo
GeneCentric secures $8m to launch liquid biopsy platform
GeneCentric Therapeutics has earned an initial $8m in a Series C funding round, marking a step towards the launch and commercialisation of GenomicsNext, an integrated platform for comprehensive liquid biopsy testing. This platform offers simultaneous gene expression measurements and DNA variant detection from a single sample of circulating tumour DNA (ctDNA). Spearheaded by Hatteras Venture Partners, the round included contributions from current investors Labcorp, Alexandria Venture Investments, and IAG Capital Partners. The investment is anticipated to sustain the company's operations through 2026. According to GeneCentric, current liquid biopsy methods primarily focus on detecting gene mutations, overlooking the aspect of gene expression. This limitation can hinder the identification of molecular subtypes and biomarkers essential for targeted cancer therapy, potentially delaying the diagnosis and treatment of oncology patients. GeneCentric developed ExpressCT technology, which forms the core of GenomicsNext. This technology measures the gene expression utilising information in ctDNA to offer a comprehensive liquid biopsy solution. The company also developed a pipeline of gene signatures and associated diagnostic tests. Its RNA-based Tumour and Immune Micro-Environment (rT(I)ME) Explorer platform and AI technology have been instrumental in deciphering complex tumour biology and detecting the population that responds to oncology therapeutics. GeneCentric Therapeutics CEO and president Mike Milburn said: 'With a single blood sample from a cancer patient, our GenomicsNext liquid biopsy platform can determine the gene expression of drug target genes, molecular subtypes, and predictive gene signatures, in addition to mutations and fusions. 'We believe our unique fragmentomics technology will become the best-in-class application for yielding greater insights and biomarker coverage from liquid biopsies to better aid diagnosis and treatment selection for patients. "We are grateful for the enthusiasm and support of our investors and expect to make the GenomicsNext platform commercially available as a powerful research tool for biopharmaceutical companies in 2025.' "GeneCentric secures $8m to launch liquid biopsy platform" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Globe and Mail
2 days ago
- Business
- Globe and Mail
Biochips Market Projected to Reach USD 37.73 Bn by 2032, Growing at 16.0% CAGR
Biochips Market, By Product Type (DNA Chips, Protein Chips, Lab-on-chip Tissue Arrays, Cell Arrays), By End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Hospitals and Diagnostic Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) According to a recent report by Coherent Market Insights, Global Biochips market is estimated to be valued at USD 13.34 Bn in 2025 and is expected to reach USD 37.73 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.0% from 2025 to 2032. Increasing application of biochips in the field of proteomics, genomics and drug discovery can drive the market growth. Extensive R&D activities in the field of healthcare and growing demand for point-of-care testing and diagnostics can also boost demand for biochips during the forecast period. Global Biochips Market Key Takeaways According to Coherent Market Insights (CMI), the global biochips market size is projected to grow at a robust CAGR of 16%, from USD 13.34 Bn in 2025 to USD 37.73 Bn by 2032. Based on product type, DNA chips segment is expected to account for over two-fifths of the global biochips market in 2025. By end user, biotechnology and pharmaceuticals segment will likely hold a market share of 35.1% by 2025. North America is anticipated to retain its dominance, holding a market share of nearly 2/5 in 2025. As per CMIs' new biochips market analysis, Asia Pacific is expected to experience fastest growth during the forecast period. Growing Demand for Personalized Medicine Boosting Market Growth Coherent Market Insights' latest biochips market research report highlights major factors driving industry growth. One such prominent growth factor is the increasing demand for personalized medicine. Biochips are a key enabling technology in personalized medicine. They enable rapid and accurate analysis of an individual's genetic and proteomic profiles. This supports pharmacogenomics, helps in creating tailored treatment plans, and facilitates targeted therapies. These capabilities are especially valuable in managing complex diseases such as cancer. Thus, growing interest in personalized medicine will continue to provide a strong impetus for the growth of biochips market in the coming years. High Cost of Biochips and Adoption of Alternative Technologies Limiting Market Growth The future biochips market outlook looks promising. However, high cost of bioships and associated equipment, along with growing usage of alternative technologies, remain a significant barrier to broader market growth. Biochips are quite expensive due to their complex manufacturing processes and the need for specialized instrumentation. This high cost limits their accessibility, particularly among small and mid-sized laboratories, thereby reducing overall biochips market demand. Many end users are turning to alternative technologies like immunoassays, qPCR, and next-generation sequencing (NGS) due to their accuracy and cost-efficiency. This trend may also negatively impact the biochips market growth in the coming years. Growing Adoption in Disease Diagnostics Creating Lucrative Growth Opportunities Biochips are being increasingly used in the diagnosis of cancer, genetic disorders, and infectious diseases due to their high accuracy and speed. Their rising adoption in disease diagnostics is expected to create lucrative growth opportunities for biochip manufacturers during the forecast period. Rising incidence of chronic and infectious diseases, such as COVID-19, is creating a strong need for rapid diagnostics. This is expected to drive demand for biochips, as they offer fast and multiplexed detection of pathogens, making them ideal for point-of-care testing. Get Up to 25% Discount on the US Tariff Impact Analysis Report: Impact of AI on the Biochips Market Artificial Intelligence (AI) is making a profound impact on the biochips market. It enhances data analysis, diagnostics, and personalized medicine. AI algorithms significantly improve the accuracy and speed of disease detection by rapidly interpreting complex biological data produced by biochips. This powerful combination accelerates drug discovery and enables real-time health monitoring. With ongoing advancements in AI, new applications and efficiencies are expected to emerge. This evolution is poised to propel the biochips market toward greater scalability and precision in delivering advanced healthcare solutions. Emerging Biochips Market Trends Growing trend of miniaturization is significantly impacting the biochips market value. Key manufacturers are focusing on developing compact biochips (e.g. lab-on-a-chip systems) with improved features for use in diagnostics, drug discovery, and personalized medicine. Expanding applications of biochips in drug discovery is expected to foster sales growth. Biochips are increasingly used in drug discovery processes, particularly for gene expression analysis, toxicity profiling, and target identification. These applications are crucial for accelerating pharmaceutical R&D, thereby driving market growth. There is a growing emphasis on studying genes and proteins to better understand disease mechanisms, identify potential therapeutic targets, and develop personalized medicine approaches. This will likely create a strong demand for biochips in high-throughput research. Shift toward point-of-care testing (POCT) is expected to create lucrative growth avenues for biochip companies. Portable biochips are being widely used in POCT devices for faster diagnostics at the patient's location. Ongoing advancements in biochip manufacturing will also support market expansion. Improvements in microfluidics, microarray technology, and semiconductor biochip development are significantly enhancing capabilities of biochips. Analyst's View ' The global biochips market is expected to record robust growth, owing to increasing incidence of chronic and infectious diseases, rising demand for personalized medicines, and advancements in biochip manufacturing,' said senior analyst Abhijeet Kale. Current Events and Their Impact on the Biochips Market Competitor Insights Key companies listed in biochips market report: - LinguaFlex - Inspire Medical Systems, Inc. - Medtronic - LivaNova PLC - SomnoMed - Nihon Kohden Corporation - Siesta Medical Inc. - ResMed - Koninklijke Philips N.V. - Somnowell - Nyxoah SA - Fisher & Paykel Healthcare Limited - VYAIRE - Natus Medical Incorporated - Nox Medical - Drive DeVilbiss International - CLEVELAND MEDICAL DEVICES INC. - Advanced Brain Monitoring, Inc. - CONTEC MEDICAL SYSTEMS CO., LTD Key Developments In January 2025, Coherent Corp launched its new pinhole array biochips. These biochips are specifically designed for medical diagnostics, with a strong focus on gene sequencing applications. In May 2025, Archer Materials Limited partnered with Paragraf Limited for Biochip development. This partnership is intended to help Archer advance its Biochip for at-home testing of chronic kidney disease. Market Segmentation By Product Type DNA Chips Cancer Diagnosis and Treatment Gene Expression SNP Genotyping Genomics Drug Discovery Agricultural Biotechnology Others Protein Chips Proteomics Expression Profiling Diagnostics HTS Others Lab-on-chip IVD & POC Others Tissue Arrays Cell Arrays By End User Biotechnology and Pharmaceutical Companies Academic & Research Institutes Hospitals and Diagnostic Centers Others About Us:Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Media Contact Company Name: Coherent Market Insights Contact Person: Mr. Shah Email: Send Email Phone: + 12524771362 Address: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States Burlingame City: Burlingame State: California Country: United States Website:
Forbes
3 days ago
- Business
- Forbes
Illumina's New CIO Brings R&D Mindset As AI Transforms Genomics
Illumina this month named Mark Field as its next Chief Information Officer, adding a veteran technology and R&D executive to its leadership team as the DNA sequencing giant navigates the next wave of AI and innovation in genomics. Field, who started earlier this month, is based in San Diego and reports to CEO Jacob Thaysen. He succeeds Carissa Rollins, who retired in April. With a three-decade career in enterprise IT and life sciences, Field brings a blend of corporate technology and scientific R&D experience to the role. Illumina CIO Mark Field He began his career at Oracle in 1995, gaining early insight into the internet's disruptive potential. It's a shift he sees mirrored today with the rise of AI and breakthroughs in personalized medicine. 'For the genomic age, it feels just like 1995,' Field said in an interview. Following his time at Oracle, Field led technology at Life Technologies, a life sciences company later acquired by Thermo Fisher Scientific. He was CTO at Thermo Fisher before joining Insulet Corporation, which develops medical devices for people with diabetes and other conditions. Each role reinforced his interest in how digital tools and data can accelerate scientific discovery and directly improve health outcomes, he said. Over the past few weeks, Field has been meeting teams and working to understand the ins and outs of Illumina's operations as he develops a roadmap for the future. 'My goal is to be the best partner and deliver value to the various businesses,' he said. Field says his past experience leading R&D functions in addition to corporate IT makes him well equipped to be a strong partner with that organization at Illumina. R&D is "a completely different way to perceive the world, about getting out in front, having the best product,' he said. While it's a different mindset than the one usually held by IT, technology, data and software are key to progress across both functions. Headquartered in San Diego, Illumina sells genetic sequencing products and services to medical researchers and other customers around the world. Its products are used in applications across life sciences, oncology, reproductive health, agriculture, among other segments. Illumina reported $4.3 billion in revenue for fiscal year 2024. In its most recent earnings report, the company lowered its full-year guidance and announced a $100 million cost reduction program amid ongoing geopolitical and tariff-related impacts, including a ban on imports of Illumina's products in China. Even as the company grapples with near-term headwinds, Field remains optimistic about its long-term trajectory as innovation in science and technology continues to accelerate. 'I'm more thrilled today than I was yesterday, and more thrilled yesterday than I was when I started,' he said. 'I knew it was a great company, but its potential is what's truly exciting me now.'
Yahoo
3 days ago
- Business
- Yahoo
3 Top Genomics Stocks to Add to Your Portfolio in 2025
An updated edition of the March 28, 2025, article. The rapid evolution of genomics, the study of genes and their functions, in recent times has paved the way for a revolutionary era in genetic medicine. Given the constant need for innovative medical treatments, genomics holds the key to the future of the medical world. In simpler terms, genomics includes the study of a complete set of genes, their work process and way of interacting with each other and the environment. The primary focus is to evaluate all the genes of an organism rather than individual genes. Of late, there have been several breakthroughs in this field, attracting the attention of pharma and biotech companies. Genetic information is being used to evaluate individual responses to drugs, leading to the development of targeted therapies. Interestingly, genomics has ushered in innovative concepts, such as synthetic biology, which applies engineering principles to biology. Synthetic biology products serve life sciences researchers across a variety of healthcare applications, including drug discovery, disease detection, enzyme engineering, gene editing and basic academic research. The recent spotlight on companies in the evolving genomics sector can be attributed to a drastic reduction in the cost, accuracy, and time required to map an individual's entire genome. A major player in this field is Illumina ILMN, a global leader in sequencing and array-based solutions for genetic and genomic analysis. While some companies are utilizing genetic sequencing to develop solutions not only for healthcare but also for other areas, diagnostic companies leverage sequencing data to identify specific genetic variations and map them to a known condition. Another breakthrough is the development of genome editing approaches, such as CRISPR/Cas9 technology. Gene editing companies, such as BEAM Therapeutics BEAM and CRISPR Therapeutics AG CRSP, hold potential to treat and cure diseases caused by genetic variants. As the name suggests, they make changes or correct defects in the organism's DNA. Per estimates, the genomics market will reach $157.47 billion by 2033. Per Grandview research, the global synthetic biology market size was valued at $16.22 billion in 2024 and is projected to witness a CAGR of 17.30% from 2025 to 2030. If you're looking to capitalize on this trend, our Genomics and Synthetic Biology screen makes it easy to identify high-potential stocks at any given time. At present, investors can consider adding stocks like Intellia Therapeutics NTLA, uniQure QURE and Verve Therapeutics VERV to their portfolio. Explore 30 cutting-edge investment themes with Zacks Thematic Screens and uncover your next big opportunity. Intellia Therapeutics is a clinical-stage gene editing company, focused on developing drugs with CRISPR-based therapies. NTLA is leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. The in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. NTLA's lead in vivo product candidates are nex-z for the treatment of ATTR amyloidosis and NTLA-2002 for the treatment of HAE. NTLA-2002 is a wholly owned, investigational in vivo CRISPR-based therapy designed to knock out the kallikrein B1 gene in the liver, with the goal of achieving lifelong control of HAE attacks after a single dose. Nex-z is an investigational CRISPR-based therapy designed to inactivate the TTR gene in liver cells, thereby preventing the production of TTR protein for the treatment of ATTR amyloidosis. Both are currently in phase III studies. NTLA has collaborated with Regeneron for Nex-z. This Zacks Rank #2 (Buy) company is also advancing ex vivo applications to address immuno-oncology and autoimmune diseases, where CRISPR is used as the tool to create the engineered cell therapy outside the body. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. uniQure is advancing a focused pipeline of innovative gene therapies for the treatment of Huntington's disease, amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1 ('SOD1-ALS'), refractory mesial temporal lobe epilepsy ('mTLE') and Fabry disease. The company has made good pipeline progress. The FDA recently granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington's disease. In March 2025, QURE held a Type B meeting with the FDA to discuss chemistry, manufacturing and controls requirements for AMT-130, in support of a planned biologics license application ('BLA') submission. An additional Type B meeting (focused on the pivotal statistical analysis plan) was also held. The company is also conducting a phase I/IIa study (GenTLE) on AMT-260 for the treatment of MTLE in the United States. A phase I/IIa study on AMT-191 for the treatment of Fabry disease is also ongoing. AMT-162 is being evaluated for the treatment of SOD1-ALS in a phase I/II study. The successful development of any of these candidates will be a significant boost for this Zacks Rank #2 company. Verve Therapeutics is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease (CVD). The primary objective is to transition CVD treatment from chronic therapies to single-course, gene-editing medicines. VERV is developing a pipeline of gene editing programs targeting the three lipoprotein pathways — low-density lipoprotein, or LDL, triglyceride-rich lipoproteins, and lipoprotein(a), or Lp(a) — that drive atherosclerotic cardiovascular disease (ASCVD), the most common form of CVD. VERV's lead clinical-stage programs target the PCSK9 and ANGPTL3 genes, which have been extensively validated as targets for lowering LDL cholesterol, or LDL-C. VERVE-102 targets PCSK9 and is designed to permanently turn off the PCSK9 gene in the liver. The candidate is being evaluated in the open-label phase Ib Heart-2 study. The study is designed to evaluate the safety and tolerability of VERVE-102 in adult patients with heterozygous familial hypercholesterolemia, or HeFH, and/or premature coronary artery disease. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver. VERVE-201 is being evaluated in the open-label phase Ib study designed to evaluate the safety and tolerability in adult patients with refractory hypercholesterolemia. VERVE-301 is being developed in collaboration with Lilly. The company also carries a Zacks Rank #2. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report Beam Therapeutics Inc. (BEAM) : Free Stock Analysis Report uniQure N.V. (QURE) : Free Stock Analysis Report Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Verve Therapeutics, Inc. (VERV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Anne Wojcicki's bid to buy back 23andMe may not end a legal fight over DNA customer data
Anne Wojcicki's winning bid to reclaim control of 23andMe (MEHCQ) doesn't necessarily end the fight over what happens to the DNA of 15 million people collected by the bankrupt consumer genomics company. A nonprofit controlled by Wojcicki, TTAM Research Institute, has outbid large-cap drugmaker Regeneron (REGN) amid mounting opposition to a proposed sale. Wojcicki was the co-founder and former CEO of 23andMe. A hearing to discuss approval of the purchase is set for Wednesday. A bankruptcy judge's approval is required to go ahead with the transaction. The winning bid came days after members of Congress questioned Wojcicki about the fate of the DNA data, and more than half of states across the country sued 23andMe's bankruptcy estate to stop the sale of its consumers' biological samples, health-related traits, and medical records. Brian Focht, a data privacy lawyer, said the sensitivity of the data is a good reason for the court and consumers to view TTAM's proposal with caution. 'This is information that's immutable. It's a permanent part of your identity,' Focht said. 'You can't change the way that you can change almost everything, including your social security number, your name, and your bank account number.' Although TTAM's ownership of the data may resolve some of the privacy concerns, a consumer watchdog report filed with the bankruptcy court last Wednesday said a sale of 23andMe to any buyer, including TTAM, creates unique challenges. That's because it involves the possible transfer of consumer data that is "significantly more sensitive" than consumer data involved in prior bankruptcy cases. While Wojcicki has pledged to effectively run TTAM as the same type of business as 23andMe, Focht noted that she was in charge during a period in 2023 when 23andMe disclosed privacy and cybersecurity lapses that exposed data, potentially including genetic data, on approximately 7 million customers. "So it's probably a bit foolishly optimistic to think that her re-takeover of the company will somehow make all the concerns disappear," he said. The bankruptcy court's watchdog expressed the same concern in a report filed Wednesday with the court. Because TTAM is a nonprofit, it said, it could possibly operate outside the scope of many data protection laws, potentially creating a "privacy and security enforcement and accountability vacuum." "That's a legitimate concern," said Gary Kibel, a privacy and data security partner with the law firm Davis+Gilbert, because most state consumer privacy laws do not apply to nonprofit entities. 23andMe did not respond to a request for comment on the proposed bid. The question of 23andMe's right to sell the data has not been tested in court. And because it is a direct-to-consumer company, as opposed to a healthcare provider, the data is not protected by federal laws, such as HIPAA. Nineteen states do have laws that require a company to obtain consent to process sensitive customer information. And some states have adopted stand-alone consumer health data privacy laws that create a higher standard of consent for the transfer of consumer health data to third parties, Kibel said. A regulator could consider whether a transfer of sensitive consumer data complies with those state laws. Outside of those state rules, Kibel said, every state has "UDAAP" laws that protect consumers against unfair or deceptive acts and practices, and the US Federal Trade Commission has made it clear that bankruptcy does not automatically entitle a company to transfer consumers' personal information. Last week, 28 state attorneys general and the attorney general for the District of Columbia filed complaints in 23andMe's bankruptcy case claiming that the company's assets don't include its consumers' DNA and other personal information. And that's especially for those who signed agreements with the company prior to June 8, 2022, when terms stated that '23andMe will not sell, lease, or rent your individual-level information to a third party for research purposes without your explicit consent," the states alleged. 23andMe later amended its privacy policy to include the transfer of consumer data in the event of a bankruptcy. The privacy lawyers said that whether the policy change holds up under a challenge would depend on whether or not state law prohibits it. Daniel Gielchinsky, a bankruptcy lawyer with DGIM Law, said, "In light of the [watchdog's] report and the objections filed by the various states, it is likely that the bankruptcy court would not give [TTAM] the same rights in the data that 23andMe currently has." Another wrinkle for the bankruptcy court, according to Focht, is that the state law that applies to each of 23andMe's consumers depends on where they currently live, and not where they lived at the time they consented to 23andMe's terms. The watchdog's report raised a third concern over TTAM's purchase of 23andMe. It said the company's telemedicine subsidiary, Lemonaid Health, would potentially be included in a sale and the relationship between the companies could prove complicated given the "evolving legal landscape for personal health records and the sensitivity with health data." Lawmakers have expressed concern that foreign nations could gain access to Americans' genetic data. In 2015, 23andMe accepted a $10 million investment from WuXi Healthcare Ventures, which had ties to the Chinese Communist Party. The company has since been bought by Frontline BioVentures, which formed a new healthcare investment venture known as 6 Dimensions Capital. During testimony before the House Oversight Committee on Wednesday, Wojcicki promised that 23andMe would not sell customers' DNA data to foreign adversaries, specifically China, Russia, and North Korea. Uttara Ananthakrishnan, a professor of information systems at Carnegie Mellon University, said use of genetic data should be held to a higher level of consent than the consent required for other data, like credit scores, search data, and location data. 'I don't think people have realized the seriousness of this all, because it's really novel,' Ananthakrishnan said. 'Thirty years down the line, we don't know what's going to happen with this data, what kind of new technologies are going to come in. You might have [an AI model] trained on really granular genetic data that can predict job outcomes, insurance.' But Kibel said, "Maybe this spurs Congress to realize, 'You know what? We need a federal comprehensive consumer privacy law, because we don't have one.'" Alexis Keenan is a legal reporter for Yahoo Finance. Follow Alexis on X @alexiskweed. Click here for in-depth analysis of the latest stock market news and events moving stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
